Lupus eritematoso sistémico y embarazo

  • Carolina Franco Almada Servicio de Reumatología, Hospital Central del Instituto de Previsión Social, Asunción, Paraguay
Palabras clave: Lupus Eritematoso sistémico, embarazo, fertilidad, complicaciones, hidroxicloroquina, bloqueo cardíaco

Resumen

El lupus eritematoso sistémico es una enfermedad autoinmune con alta prevalencia en mujeres, principalmente en edad fértil. Esta enfermedad puede causar una considerable morbimortalidad tanto materna como fetal durante el embarazo. Se ha demostrado que la remisión de la enfermedad y/o su correcto manejo pueden disminuir de forma significativa las complicaciones materno-fetales por lo que el conocimiento sobre ellas es fundamental.

Citas

(1) Cooper GS, Gilbert KM, Greidinger EL, et al. Recent advances and opportunities in research on lupus: environmental influences and mechanisms of disease. Environ Health Perspect. 2008; 116: 695-702.

(2) Somers EC, Thomas SL, Smeeth L, et al. Incidence of systemic lupus erythematosus in the United Kingdom, 1990-1999. Arthritis Rheum. 2007; 57:6128.

(3) Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007; 56:2092–2094.

(4) Karpouzas GA, Kitridou RC. The mother in systemic lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Lupus Erythematosus 7th Ed, Philadelpia: Lippincott Williams & Wilkins: 2007. p.992–1038.

(5) Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and Regulatory T-Cell Paradigm in Pregnancy. Am J Reprod Immunol. 2010;63: 601-10.

(6) Leroy C, Rigot JM, Leroy M, Decanter C, Le Mapihan K, Parent AS, et al. Immuno-suppressive drugs and fertility. Orphanet J Rare Dis 2015;10:136.

(7) Mackillop LH, Germain SJ, Nelson-Piercy C. Systemic lupus erythematosus. BMJ.2007; 335: 933-936.

(8) Ruiz-Irastorza G, Khamashta MA. Lupus and pregnancy: Integrating clues fromthe bench and bedside. Eur J Clin Invest. 2011; 41: 672–89.

(9) Kim MY, Buyon JP, Guerra MM, Rana S, Zhang D, Laskin CA, et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies:

results of the PROMISSE study. Am J Obstet Gynecol. 2016;214:108. e1–108.e14.

(10) Lima F, Buchanan NM, Khamashta MA, Kerslake S, Hughes GR. Obstetric outcome in systemic lupus erythematosus. Semin Arthritis

Rheum; 1995 25(3):184–192.

(11) Chakravarty EF, Colon I, Langen ES, et al. Factors that predict prematurity and preeclampsia in pregnancies that are complicated by systemic lupus erythematosus. Am J Obstet Gynecol; 2005

(6):1897–1904.

(12) Moroni G, Ponticelli C. The risk of pregnancy in patients with lupus nephritis. J Nephrol; 2003 16(2):161–167.

(13) Qazi UM, Petri M. Autoantibodies, low complement, and obesity predict preeclampsia in SLE: A case-control study. Arthritis Rheum; 2006 54(9 supplement):S264.

(14) Clark CA, Spitzer KA, Nadler JN, Laskin CA. Preterm deliveries in women with systemic lupus erythematosus. J Rheumatol; 2003 30(10):2127–2132.

(15) Georgiou PE, Politi EN, Katsimbri P, Sakka V, Drosos AA. Outcome of lupus pregnancy: a controlled study. Rheumatology (Oxford); 2000 39(9):1014–1019.

(16) Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum; 2005 52(2):514–521.

(17) Wong KL, Chan FY, Lee CP. Outcome of pregnancy in patients with systemic lupus erythematosus. A prospective study. Arch Intern Med; 1991 151(2):269–273.

(18) Magid MS, Kaplan C, Sammaritano LR, Peterson M, Druzin ML, Lockshin MD. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol; 1998 179(1):226–234.

(19) Yasmeen S, Wilkins EE, Field NT, Sheikh RA, Gilbert WM. Pregnancy outcomes in women with systemic lupus erythematosus. J Matern Fetal Med; 2001 10(2):91–96.

(20) Tincani A, Faden D, Tarantini M, et al. Systemic lupus erythema tosus and pregnancy: a prospective study. Clin Exp Rheumatol; 1992 10(5):439–446.

(21) Julkunen H, Kaaja R, Palosuo T, Gronhagen-Riska C, Teramo K. Pregnancy in lupus nephropathy. Acta Obstet Gynecol Scand; 1993 72(4):258–263.

(22) Huong DL, Wechsler B, Vauthier-Brouzes D, Beaufils H, Lefebvre G, Piette JC. Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis Jun. 2001;

(6):599–604.

(23) Moroni G, Quaglini S, Banfi G, et al. Pregnancy in lupus nephritis. Am J Kidney Dis; 2002; 40(4):713–720.

(24) Jungers P, Dougados M, Pelissier C, et al. Lupus nephropathy and pregnancy. Report of 104 cases in 36 patients. Arch Intern Med Apr. 1982; 142(4):771–776.

(25) Oviasu E, Hicks J, Cameron JS. The outcome of pregnancy in women with lupus nephritis. Lupus Nov.1991; 1(1):19–25.

(26) Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007; 33:237–52.

(27) Wagner SJ, Craici I, Reed D, Norby S, Bailey K, Wiste HJ, et al. Maternal and fetal outcomes in pregnant patients with active lupus nephritis. Lupus. 2009; 18(4): 342–7.

(28) Gladman DD, Tandon A, Ibanez D, UrowitzMB. The effect of lupus nephritis on pregnancy outcome and fetal andmaternal complications. J Rheumatol. 2010; 37: 754–8.

(29) Wang W, Li Y. Clinical outcomes and predictors of fetal and maternal consequences of pregnancy in lupus nephritis. Int Urol Nephrol. 2015; 47: 1379–85.

(30) Borella E, Lojacono A, Gatto M, Andreoli L, Taglietti M, Iaccarino L, et al. Predictors of maternal and fetal complications in SLE patients:a prospective study. Immunol Res. 2014; 60(2–3):170–6.

(31) H. Yang, H. Liu, D. Xu et al., “Pregnancy-related systemic lupus erythematosus: clinical features, outcome and risk factors of disease flares—a case control study,” PLoS ONE (Internet).2014 Ago (citado 13 Ago 2014):9 (8) (aprox 7 p). Disponible en https://doi.org/10.1371/journal.pone.0104375

(32) Petri M, Howard D, Repke J. Frequency of lupus flare in pregnancy. The Hopkins lupus pregnancy center experience. Arthritis Rheum. 1991; 34(12):1538–45.

(33) Moroni G, Ponticelli C. Rapidly progressive crescentic glomerulonephritis: early treatment is a must. Autoimmun Rev. 2014; 13(7):723–9.

(34) Ponticelli C,Moroni G. Flares in lupus nephritis: incidence, impacton renal survival and management. Lupus. 1998; 7(9):635–8.

(35) Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal out come in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology. 2002; 41:643–650.

(36) Buyon JP, Kim MY, Guerra MM, Laskin CA, Petri M, Lockshin MD, et al. Predictorsof pregnancy outcomes in patients with lupus: A cohort study. Ann Intern Med.2015; 163: 153–63.10.

(37) Ostensen M, Andreoli L, Brucato A, Cetin I, Chambers C, Clowse ME, et al. State of the art: Reproduction and pregnancy in rheumatic diseases. Autoimmun Rev. 2015; 14: 376–86.

(38) Ruiz-Irastorza G, Khamashta MA, Gordon C, Lockshin MD, Johns KR, Sammaritano L, et al. Measuring systemic lupus erythematosus activity during pregnancy: Validation of the Lupus Activity Index in Pregnancy scale. Arthritis Care Res. 2004; 51:78–82.

(39) Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing disease activity in SLE patients during pregnancy. Lupus. 1999; 8(8):677–684.

(40) Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2350–2357.

(41) Buyon JP, Tamerius J, Ordorica S, Young B, Abramson SB. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum.1992; 35(1):55–61.

(42) Clowse MEB, Magder LS, Petri M. Complement and double-stranded DNA antibodies predict pregnancy outcomes in lupus patients. Arthritis Rheum 2004; 50:S408.

(43) Hesselink DA, Aarden LA, Swaak AJ. Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. Scand J Rheumatol. 2003; 32(3):151–155.

(44) Williams RC Jr, Harmon ME, Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol. 2005; 32(3):454–461.

(45) Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther. 2006; 8(3):209.

(46) Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum. 2003;48(11):3207–3211.

(47) The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med1991; 324(3):150–154.

(48) Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation. 2011; 124:1927–35.

(49) Izmirly PM, Buyon JP, Saxena A. Neonatal lupus: advances in understanding pathogenesis and identifying treatments of cardiac disease. Curr Opin Rheumatol. 2012; 24:466–72.

(50) Jaeggi E, Laskin C, Hamilton R, Kingdom J, Silverman E. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol. 2010; 55: 2778–84.

(51) Brucato A, Doria A, Frassi M, Castellino G, Franceschini F, Faden D, et al. Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: A prospective controlled study. Lupus. 2002; 11: 716–21.

(52) Peart E, Clowse ME. Systemic lupus erythematosus and pregnancy outcomes: An update and review of the literature. Curr Opin Rheumatol. 2014; 26:118–23.

(53) Martínez López JA, García Vivar M.L, Cáliz R, Freire M, Galindo M, et al. Recomendaciones sobre actuaciones a seguir durante la edad fértil, el embarazo, posparto y lactancia en pacientes con enfermedades reumáticas inflamatorias autoinmunes. Reumatol Clin 2017; 13:264-81.

(54) Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, Khamashta MA, Kim MY, Saxena A, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody- associated cardiac manifestations of neonatal lupus. Circulation. 2012; 126: 76–82.

(55) Tunks RD, Clowse ME, Miller SG, Brancazio LR, Barker PC. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol. Am J Obstet Gynecol 2013; 208:64-67

Publicado
2018-06-08
Cómo citar
Franco Almada, C. (2018). Lupus eritematoso sistémico y embarazo. Revista Paraguaya De Reumatología, 4(1), 18-24. Recuperado a partir de http://revista.spr.org.py/index.php/spr/article/view/84
Sección
REVISIÓN